37 related articles for article (PubMed ID: 23627671)
21. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Guo W; Wang H; Zhao W
Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
[TBL] [Abstract][Full Text] [Related]
22. [Relationship between the long type PML-RAR alpha and the prognosis of patients with acute promyelocytic leukemia].
Tan YH; Wang HW; Zhang ZP; Liu W; Guo HM; Zhu L; Zhang L
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):44-7. PubMed ID: 18512315
[TBL] [Abstract][Full Text] [Related]
23. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
24. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
[TBL] [Abstract][Full Text] [Related]
25. [All-trans retinoic acid therapy in acute promyelocytic leukemia--current status and prospect].
Kitamura K; Takeshita A; Ono R; Naoe T
Rinsho Ketsueki; 1996 Sep; 37(9):760-5. PubMed ID: 8914458
[No Abstract] [Full Text] [Related]
26. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia.
Lo Coco F; Diverio D; Falini B; Biondi A; Nervi C; Pelicci PG
Blood; 1999 Jul; 94(1):12-22. PubMed ID: 10381493
[No Abstract] [Full Text] [Related]
27. The short isoform of the long-type PML-RARA fusion gene in acute promyelocytic leukaemia lacks sensitivity to all-trans-retinoic acid.
Tan Y; Bian S; Xu Z; Chen X; Qi X; Ren F; Li L; Guo H; Xu A; Zhang L; Wang H
Br J Haematol; 2013 Jul; 162(1):93-7. PubMed ID: 23627671
[TBL] [Abstract][Full Text] [Related]
28. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
29. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
30. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
Nasr R; Lallemand-Breitenbach V; Zhu J; Guillemin MC; de Thé H
Clin Cancer Res; 2009 Oct; 15(20):6321-6. PubMed ID: 19808868
[TBL] [Abstract][Full Text] [Related]
31. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
32. The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies.
de Thé H; Le Bras M; Lallemand-Breitenbach V
J Cell Biol; 2012 Jul; 198(1):11-21. PubMed ID: 22778276
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
